2023
Translating Evidence-based Approaches into optimal Care for individuals at High-risk of ASCVD: Pilot testing of case-based e-learning modules and design of the TEACH-ASCVD study
Clegg K, Schubert T, Block R, Burke F, Desai N, Greenfield R, Karalis D, Kris-Etherton P, McNeal C, Nahrwold R, Peña J, Plakogiannis R, Wong N, Jones L. Translating Evidence-based Approaches into optimal Care for individuals at High-risk of ASCVD: Pilot testing of case-based e-learning modules and design of the TEACH-ASCVD study. Journal Of Clinical Lipidology 2023, 17: 592-601. PMID: 37550150, DOI: 10.1016/j.jacl.2023.07.007.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseaseEvidence-based guidelinesASCVD patientsDetailed patient historyCause of deathClinical best practicesBetter patient careEvidence-based managementU.S. health systemEvidence-based approachOptimal careCardiovascular diseasePatient historyDiagnostic criteriaClinician groupsField of lipidologyPatient careHealth systemCliniciansPatientsCarePilot testingGuidelinesFocus groupsElicit feedbackMoving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease
Faridi K, Desai N. Moving toward combination lipid-lowering therapy for all patients with atherosclerotic cardiovascular disease. American Journal Of Preventive Cardiology 2023, 14: 100491. PMID: 36969953, PMCID: PMC10036885, DOI: 10.1016/j.ajpc.2023.100491.Commentaries, Editorials and Letters
2021
Prevention of atherosclerotic cardiovascular disease in South Asians in the US: A clinical perspective from the National Lipid Association
Kalra D, Vijayaraghavan K, Sikand G, Desai N, Joshi P, Mehta A, Karmally W, Vani A, Sitafalwalla S, Puri R, Duell P, Brown A. Prevention of atherosclerotic cardiovascular disease in South Asians in the US: A clinical perspective from the National Lipid Association. Journal Of Clinical Lipidology 2021, 15: 402-422. PMID: 33846108, DOI: 10.1016/j.jacl.2021.03.007.Peer-Reviewed Original ResearchConceptsAtherosclerotic cardiovascular diseaseSouth AsiansLack of physical exerciseRates of atherosclerotic cardiovascular diseaseCholesterol treatment guidelinesCardiovascular diseasePrevention of atherosclerotic cardiovascular diseaseNational Lipid AssociationPrevalence of atherosclerotic cardiovascular diseaseAge-matched peoplePractical prevention strategiesHealthcare providersPhysical exerciseDietary advicePrevention strategiesDietary factorsEarly screeningRisk enhancementTreatment guidelinesConsensus documentVisceral adiposityExpert consensus documentAsiansClinical perspectiveLipid association
2020
1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States
REIFSNIDER O, PIMPLE P, STARGARDTER M, BRAND S, DESAI N, SHETTY S. 1158-P: Cost-Effectiveness of Empagliflozin vs. Liraglutide as Second-Line Therapy for Type 2 Diabetes in the United States. Diabetes 2020, 69 DOI: 10.2337/db20-1158-p.Peer-Reviewed Original ResearchBoehringer Ingelheim PharmaceuticalsUse of empagliflozinT2D patientsCardiovascular diseaseAdverse eventsUnited Kingdom Prospective Diabetes Study (UKPDS) risk equationsGLP-1 receptor agonistsT2D-related complicationsSecond-line therapyType 2 diabetesClinical trial resultsTreatment-induced changesBackground metforminCVD subgroupsCV deathRenal outcomesHazard ratioClinical outcomesSGLT2 inhibitorsCVS CaremarkMyocardial infarctionReceptor agonistSpouse/partnerImproved outcomesDrug classes
2019
Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
Desai N, Rowan C, Alvarez P, Fogli J, Toto R. Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients. Journal Of Drug Assessment 2019, 8: 2-2. PMCID: PMC6764378, DOI: 10.1080/21556660.2019.1658287.Peer-Reviewed Original ResearchContinuous exposureRenin angiotensin aldosterone system inhibitor therapyAldosterone system inhibitor therapyDevelopment of hyperkalemiaCornerstone of therapyRetrospective cohort studyOptum Clinformatics DataMartMEq/LNational Health InsuranceBinder therapyHK cohortHyperkalemia treatmentPotassium bindersRAASi therapyIndex dateCohort studyInhibitor therapyContinuation ratesMean ageDiagnosis codesITT groupCardiovascular diseaseClinformatics DataMartMedicare patientsPatiromer
2015
National assessment of statin therapy for patients with acute myocardial infarction, 2001–11: insight from the China PEACE-Retrospective Acute Myocardial Infarction study
Zhang L, Li J, Li X, Nasir K, Zhang H, Wu Y, Hu S, Wang Q, Downing N, Desai N, Masoudi F, Spertus J, Krumholz H, Jiang L, Group O. National assessment of statin therapy for patients with acute myocardial infarction, 2001–11: insight from the China PEACE-Retrospective Acute Myocardial Infarction study. The Lancet 2015, 386: s42. DOI: 10.1016/s0140-6736(15)00623-6.Peer-Reviewed Original ResearchIntensive statin therapyAcute myocardial infarctionAcute Myocardial Infarction StudyStatin therapyMyocardial Infarction StudyMyocardial infarctionStatin useCardiovascular diseaseLow-density lipoprotein cholesterolStatin therapy useLong-term mortalityUse of statinsNumber of patientsTwo-stage random sampling designMultilevel logistic regression modelsCochran-Armitage testLogistic regression modelsWestern rural regionStatin regimensEligible patientsHospital mortalityLipoprotein cholesterolFamily Planning CommissionIntensive therapyTherapy use